Retatrutide: Phase-2 trial Retatrutide is an investigational triple agonist (GLP-1, GIP and glucagon receptors), adding a third hormone target to potentially boost metabolism further
This finding indicate that current fasting guidelines may be insufficient for patients on GLP-1 RAs, thereby increasing their aspiration risk [19]
Deficiency is common, especially in people who follow a vegetarian or vegan diets
Backed by ongoing support from our team, these once-weekly injections are a game-changer for those seeking chronic weight management and a healthier lifestyle
The cost of the weight loss management program at CPRS varies, as it is customized to each patients specific needs, including the choice between semaglutide, tirzepatide, or both